[Published] 2020/3/18 [Last updated] 2024/10/11
Frontiers in Medicine 2024
The original article by Dr. Jun Sato et.al. from our department has been published in “Frontiers in Medicine”. It presents research suggesting that there are regional differences in the incidence of drug-induced lung injury (including drug-induced pneumonia and drug-induced interstitial lung disease) in Japan, Europe (EU), and the United States.
The study used the adverse event reporting database provided by the U.S. Food and Drug Administration (FDA) to analyze large-scale, real-world clinical data.
APODDC 2024
Dr. Takafumi Koyama and Dr. Jun Sato from our department joined APODDC(Asia Pacific Oncology Drug Development Consortium) Forum 2024 in National Cancer Centre Singapore.
Presentations：AACR 2024
Dr. Yuki Katsuya from our department presented a poster at AACR(American Association for Cancer Research) Annual Meeting 2024.
- Abstract CT062: A phase 1 study of tamnorzatinib (ONO-7475), an Axl/Mer dual inhibitor, alone and in combination with nivolumab in patients with advanced or metastatic solid tumors
Presentations：ESMO 2023
Dr. Ryo Sadachi (Biostatistics Division) and Dr. Mao Okada (Department of Experimental Therapeutics) presented a poster at ESMO (European Society for Medical Oncology) 2023.
- #1880: Regional differences in drug-induced lung disease (DILD) caused by anticancer drugs between the US, EU and Japan: a large-scale data-based analysis using the FDA Adverse Event Reporting System (FAERS)
Presentations：ASCO 2023
At ASCO(American Society of Clinical Oncology)2023, Dr. Yuji Uehara, who was a resident in our department from April to June 2022, made a poster presentation.
- Impact of patient travel time on disparities in precision oncology clinical trials. Yuji Uehara, Takafumi Koyama, Yuki Katsuya, Jun Sato, Noboru Yamamoto; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan DOI: 10.1200/JCO.2023.41.16_suppl.3113
Dr. Takafumi Koyama from our department also made a poster presentation.
- Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b/2 trial (NCCH1806/MK004). Takafumi Koyama, Toshio Shimizu, Yuki Kojima, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Tatsunori Shimoi, Hitoshi Ichikawa, Shinji Kohsaka, Akihiko Yoshida, Naoko Matsui, Kenichi Nakamura, Noboru Yamamoto, Kan Yonemori DOI: 10.1200/JCO.2023.41.16_suppl.11544